PURPOSE: Childhood cancer survivors have an increased risk of secondary sarcomas. To better identify those at risk, the relationship between therapeutic dose of chemotherapy and radiation and secondary sarcoma should be quantified. METHODS AND MATERIALS: We conducted a nested case-control study of secondary sarcomas (105 cases, 422 matched controls) in a cohort of 14,372 childhood cancer survivors. Radiation dose at the second malignant neoplasm (SMN) site and use of chemotherapy were estimated from detailed review of medical records. Odds ratios (ORs) and 95% confidence intervals were estimated by conditional logistic regression. Excess odds ratio (EOR) was modeled as a function of radiation dose, chemotherapy, and host factors. RESULTS: Sarcomas occurred a median of 11.8 years (range, 5.3-31.3 years) from original diagnosis. Any exposure to radiation was associated with increased risk of secondary sarcoma (OR = 4.1, 95% CI = 1.8-9.5). A dose-response relation was observed, with elevated risks at doses between 10 and 29.9 Gy (OR = 15.6, 95% CI = 4.5-53.9), 30-49.9 Gy (OR = 16.0, 95% CI 3.8-67.8) and >50 Gy (OR = 114.1, 95% CI 13.5-964.8). Anthracycline exposure was associated with sarcoma risk (OR = 3.5, 95% CI = 1.6-7.7) adjusting for radiation dose, other chemotherapy, and primary cancer. Adjusting for treatment, survivors with a first diagnosis of Hodgkin lymphoma (OR = 10.7, 95% CI = 3.1-37.4) or primary sarcoma (OR = 8.4, 95% CI = 3.2-22.3) were more likely to develop a sarcoma. CONCLUSIONS: Of the risk factors evaluated, radiation exposure was the most important for secondary sarcoma development in childhood cancer survivors; anthracycline chemotherapy exposure was also associated with increased risk.
PURPOSE:Childhood cancer survivors have an increased risk of secondary sarcomas. To better identify those at risk, the relationship between therapeutic dose of chemotherapy and radiation and secondary sarcoma should be quantified. METHODS AND MATERIALS: We conducted a nested case-control study of secondary sarcomas (105 cases, 422 matched controls) in a cohort of 14,372 childhood cancer survivors. Radiation dose at the second malignant neoplasm (SMN) site and use of chemotherapy were estimated from detailed review of medical records. Odds ratios (ORs) and 95% confidence intervals were estimated by conditional logistic regression. Excess odds ratio (EOR) was modeled as a function of radiation dose, chemotherapy, and host factors. RESULTS:Sarcomas occurred a median of 11.8 years (range, 5.3-31.3 years) from original diagnosis. Any exposure to radiation was associated with increased risk of secondary sarcoma (OR = 4.1, 95% CI = 1.8-9.5). A dose-response relation was observed, with elevated risks at doses between 10 and 29.9 Gy (OR = 15.6, 95% CI = 4.5-53.9), 30-49.9 Gy (OR = 16.0, 95% CI 3.8-67.8) and >50 Gy (OR = 114.1, 95% CI 13.5-964.8). Anthracycline exposure was associated with sarcoma risk (OR = 3.5, 95% CI = 1.6-7.7) adjusting for radiation dose, other chemotherapy, and primary cancer. Adjusting for treatment, survivors with a first diagnosis of Hodgkin lymphoma (OR = 10.7, 95% CI = 3.1-37.4) or primary sarcoma (OR = 8.4, 95% CI = 3.2-22.3) were more likely to develop a sarcoma. CONCLUSIONS: Of the risk factors evaluated, radiation exposure was the most important for secondary sarcoma development in childhood cancer survivors; anthracycline chemotherapy exposure was also associated with increased risk.
Authors: Maureen M O'Brien; Sarah S Donaldson; Raymond R Balise; Alice S Whittemore; Michael P Link Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Peter D Inskip; Leslie L Robison; Marilyn Stovall; Susan A Smith; Sue Hammond; Ann C Mertens; John A Whitton; Lisa Diller; Lisa Kenney; Sarah S Donaldson; Anna T Meadows; Joseph P Neglia Journal: J Clin Oncol Date: 2009-07-20 Impact factor: 44.544
Authors: Gregory T Armstrong; Qi Liu; Yutaka Yasui; Joseph P Neglia; Wendy Leisenring; Leslie L Robison; Ann C Mertens Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Debra L Friedman; John Whitton; Wendy Leisenring; Ann C Mertens; Sue Hammond; Marilyn Stovall; Sarah S Donaldson; Anna T Meadows; Leslie L Robison; Joseph P Neglia Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 11.816
Authors: H C Jenkinson; D L Winter; H B Marsden; M A Stovall; M C G Stevens; C A Stiller; M M Hawkins Journal: Br J Cancer Date: 2007-07-24 Impact factor: 7.640
Authors: Mark A Applebaum; Tara O Henderson; Sang Mee Lee; Navin Pinto; Samuel L Volchenboum; Susan L Cohn Journal: Pediatr Blood Cancer Date: 2014-09-23 Impact factor: 3.167
Authors: Stephanie R McKeown; Paul Hatfield; Robin J D Prestwich; Richard E Shaffer; Roger E Taylor Journal: Br J Radiol Date: 2015-10-14 Impact factor: 3.039
Authors: Sara J Schonfeld; Diana M Merino; Rochelle E Curtis; Amy Berrington de González; Megan M Herr; Ruth A Kleinerman; Sharon A Savage; Margaret A Tucker; Lindsay M Morton Journal: JNCI Cancer Spectr Date: 2019-06-20
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162
Authors: Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng Journal: Nat Rev Clin Oncol Date: 2013-03-26 Impact factor: 66.675
Authors: Peter D Inskip; Alice J Sigurdson; Lene Veiga; Parveen Bhatti; Cécile Ronckers; Preetha Rajaraman; Houda Boukheris; Marilyn Stovall; Susan Smith; Sue Hammond; Tara O Henderson; Tanya C Watt; Ann C Mertens; Wendy Leisenring; Kayla Stratton; John Whitton; Sarah S Donaldson; Gregory T Armstrong; Leslie L Robison; Joseph P Neglia Journal: Int J Radiat Oncol Biol Phys Date: 2015-12-15 Impact factor: 7.038